Compare Abbott Laboratories (ABT) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs DENTSPLY SIRONA Inc — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while DENTSPLY SIRONA Inc trades at $11.76 (market cap $2.44B). The key difference: Abbott Laboratories is far larger — about 68.4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| ABT | XRAY | |
|---|---|---|
Market Cap | $166.94B | $2.44B |
Sector | Health | Health |
52-Week High | $136.62 | $16.85 |
52-Week Low | $82.57 | $9.64 |
Enterprise Value | $193.69B | $4.58B |
Dividend Yield | 2.63% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
XRAY trades at $12.19, up 4.64% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $0.27, missing estimates of $0.28, continuing a trend of earnings misses. Revenue declined to $3.68B in 2025 with a net loss of $598M, though gross margin remains healthy at 48.93%. Recent news highlights distribution expansions and AI-enabled product launches, supporting growth initiatives amid ongoing profitability challenges.
The outlook remains mixed: analyst consensus is a 'Hold' with a $12.50 price target, near current levels. Upside potential exists from digital dentistry adoption and cost controls, but risks include persistent net losses, high debt-to-asset ratio of 42.88%, and competitive pressures. Investors should weigh stabilization efforts against margin headwinds and macroeconomic softness in European markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
